Search
duvelisib (Copiktra)
Indications:
- chronic lymphocytic leukemia
- small lymphocytic lymphoma
- follicular lymphoma
Adverse effects:
- increased serum AST, serum ALT
- pneumonitis
- dermatitis
- enteritis/colitis
- may increase risk of death [2]
Mechanism of action:
- dual PI3K inhibitor
- inbibits PI3K-delta & PI3K-gamma
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM correlations
References
- Ingram I
Duvelisib OK'd for Three Blood Cancers
Drug will need to separate itself from previous PI3K inhibitor.
MedPage Today. September 24, 2018
https://www.medpagetoday.com/hematologyoncology/leukemia/75292
- Worcester S
FDA Warns of Increased Risk of Death With CLL, Lymphoma Drug.
Medscape. June 30, 2022
https://www.medscape.com/viewarticle/976447